JP2022545226A5 - - Google Patents

Info

Publication number
JP2022545226A5
JP2022545226A5 JP2022510971A JP2022510971A JP2022545226A5 JP 2022545226 A5 JP2022545226 A5 JP 2022545226A5 JP 2022510971 A JP2022510971 A JP 2022510971A JP 2022510971 A JP2022510971 A JP 2022510971A JP 2022545226 A5 JP2022545226 A5 JP 2022545226A5
Authority
JP
Japan
Prior art keywords
receptor
item
neuron
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022510971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545226A (ja
JP7781052B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047503 external-priority patent/WO2021035179A1/en
Publication of JP2022545226A publication Critical patent/JP2022545226A/ja
Publication of JP2022545226A5 publication Critical patent/JP2022545226A5/ja
Priority to JP2024180241A priority Critical patent/JP2025004243A/ja
Application granted granted Critical
Publication of JP7781052B2 publication Critical patent/JP7781052B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022510971A 2019-08-21 2020-08-21 神経学的疾患のための組成物および方法 Active JP7781052B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180241A JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889963P 2019-08-21 2019-08-21
US62/889,963 2019-08-21
PCT/US2020/047503 WO2021035179A1 (en) 2019-08-21 2020-08-21 Compositions and methods for neurological diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180241A Division JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022545226A JP2022545226A (ja) 2022-10-26
JP2022545226A5 true JP2022545226A5 (cg-RX-API-DMAC7.html) 2023-08-29
JP7781052B2 JP7781052B2 (ja) 2025-12-05

Family

ID=72356519

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022510971A Active JP7781052B2 (ja) 2019-08-21 2020-08-21 神経学的疾患のための組成物および方法
JP2024180241A Pending JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024180241A Pending JP2025004243A (ja) 2019-08-21 2024-10-15 神経学的疾患のための組成物および方法

Country Status (7)

Country Link
US (1) US20220348635A1 (cg-RX-API-DMAC7.html)
EP (1) EP4017874A1 (cg-RX-API-DMAC7.html)
JP (2) JP7781052B2 (cg-RX-API-DMAC7.html)
CN (1) CN114746450A (cg-RX-API-DMAC7.html)
AU (2) AU2020334147A1 (cg-RX-API-DMAC7.html)
CA (1) CA3151920A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021035179A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311984A (en) 2016-07-07 2024-06-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
CN111556751B (zh) 2017-11-10 2024-07-12 霍华休斯医学研究院 经修饰的配体门控的离子通道及使用方法
AU2021329529A1 (en) * 2020-08-21 2023-04-27 Trames Bio, Inc. Compositions and methods for neurological diseases
US20250009906A1 (en) * 2021-11-19 2025-01-09 President And Fellows Of Harvard College Nociceptor-specific gene regulatory elements for the treatment of pain
US20250145687A1 (en) * 2022-01-31 2025-05-08 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
IL315059A (en) * 2022-02-18 2024-10-01 Trames Bio Inc Ion channels that open using ligands and methods of using them
EP4514831A4 (en) * 2022-04-27 2026-06-17 Hughes Howard Med Inst Chemogenetic receptors and their manufacturing and use processes
EP4702043A1 (en) * 2023-04-28 2026-03-04 Kriya Therapeutics, Inc. Chimeric modified ion channels and uses thereof for treatment of trigeminal nerve disorders
WO2025117698A1 (en) * 2023-12-01 2025-06-05 Massachusetts Institute Of Technology Ribozyme-enhanced rna trans-splicing

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0733103B1 (en) 1993-11-09 2004-03-03 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
FR2756297B1 (fr) 1996-11-22 1999-01-08 Centre Nat Rech Scient Procede de production de virus recombinants
WO1999006562A1 (en) 1997-07-31 1999-02-11 Chiron Corporation Method enabling readministration of aav vector via immunosuppression of host
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2995542A1 (en) 1997-09-05 1999-03-11 Genzyme Corporation Methods for generating high titer helper-free preparations of recombinant aav vectors
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
US6498244B1 (en) 1999-05-28 2002-12-24 Cell Genesys, Inc. Adeno-associated virus capsid immunologic determinants
WO2001023001A2 (en) 1999-09-29 2001-04-05 The Trustees Of The University Of Pennsylvania Rapid peg-modification
AU2003267174A1 (en) 2002-05-09 2003-11-11 Memory Pharmaceuticals Corporation Qm-7 and qt-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells
TW200412942A (en) 2002-08-06 2004-08-01 Abbott Lab Appetite control method
WO2004074245A2 (en) 2003-02-14 2004-09-02 Memory Pharmaceuticals Corporation Monkey alpha-7 nicotinic acetylcholine receptor and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US20060166363A1 (en) 2004-01-27 2006-07-27 Sergei Zolotukhin Modified baculovirus expression system for production of pseudotyped rAAV vector
WO2009042723A1 (en) 2007-09-25 2009-04-02 California Institute Of Technology Transgenic mice expressing hypersensitive nicotinic receptors
JP5511144B2 (ja) 2008-02-12 2014-06-04 学校法人福岡大学 てんかんモデル非ヒト哺乳動物
WO2010042799A2 (en) 2008-10-09 2010-04-15 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US11713470B2 (en) * 2017-03-20 2023-08-01 University of Pittsburgh—of the Commonwealth System of Higher Education Targeted gene therapies for pain and other neuro-related disorders
CN111556751B (zh) * 2017-11-10 2024-07-12 霍华休斯医学研究院 经修饰的配体门控的离子通道及使用方法
IL274702B2 (en) * 2017-11-27 2026-04-01 Coda Biotherapeutics Inc Compounds and methods for neurological diseases

Similar Documents

Publication Publication Date Title
JP7482549B2 (ja) 新規のマイクロジストロフィンおよび使用の関連する方法
US12263231B2 (en) Adeno-associated virus virions for treatment of epilepsy
JP2021503960A5 (cg-RX-API-DMAC7.html)
JP2022141670A5 (cg-RX-API-DMAC7.html)
RU2019103488A (ru) Способы и композиции для лечения нарушений и заболеваний, связанных с rdh12
JP7289306B2 (ja) 網膜障害を治療するための組成物及び方法
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
JP2022531809A (ja) ATPase媒介性疾患の処置のための組成物および方法
JP2023534037A5 (cg-RX-API-DMAC7.html)
RU2018112506A (ru) Лечение пигментного ретинита
JP2024513949A5 (cg-RX-API-DMAC7.html)
JP2023538130A5 (cg-RX-API-DMAC7.html)
JP2023514446A5 (cg-RX-API-DMAC7.html)
JP2021075550A (ja) グルカゴン類似ペプチド−1受容体亢進剤を含む筋減少症治療用薬学組成物
JP2022513454A (ja) AIMP2-DX2およびmiR-142の標的核酸を含むベクター、ならびにその使用
JP2022512579A5 (cg-RX-API-DMAC7.html)
JP2025508429A5 (cg-RX-API-DMAC7.html)
JP2021534206A5 (cg-RX-API-DMAC7.html)
JP2024133479A5 (cg-RX-API-DMAC7.html)
EP4008789B1 (en) Bicistronic aav vector for rna interference in als
JP2022519596A (ja) Cln3ポリヌクレオチドのアデノ随伴ウイルス送達
JP2023543361A (ja) Neurod1及びdlx2ベクター
CN115475247B (zh) β2-微球蛋白或其抑制剂的制药用途
WO2023231778A1 (zh) 用于治疗粘多糖贮积症iiia型的转基因表达盒
JP2024505197A5 (cg-RX-API-DMAC7.html)